Biologics, or large molecule pharmaceuticals are complex, highly targeted and generally expensive therapies that are a growing contributor to overall global healthcare spend. The burden on patients and payers has resulted in an increasing demand for generic alternatives to off-patent biologics, most commonly known as biosimilars.
Patent expiries in the immediate future present opportunities to serve the global population with high quality, low cost equivalents of proprietary biopharmaceuticals, commonly known as biosimilars. Our proven product development capabilities coupled with commercial reach has positioned us as a global leader in this industry with:
- Eleven biosimilars in various stages of development and commercialization
- A fully integrated biosimilar development team includes R&D, clinical operations, medical affairs and global pharmacovigilance.
- A WHO certified cGMP manufacturing facility, which includes E.coli and mammalian cell culture facilities.
Biosimilars represent an ideal opportunity for Dr. Reddy’s to accomplish its corporate mission of providing affordable and innovative medicines to help patients lead healthier lives.